A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically ...

Lastly, the company has initiated the submission of an original New Drug Application with the US Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette ...

The Billboard 200 is the United States’ main albums chart, compiled by Billboard magazine based on sales and streams in the USA. View the full Billboard 200 here.

If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway. "The three-year durability data from this ...

For the complete discussion on this regimen and information on navigating venous thrombotic events, read the full are here. TAR-200 Is Under Real-Time FDA Review for BCG-Unresponsive High-Risk NMIBC A ...

EMA's acceptance of Anktiva's application marks a significant step for NMIBC treatment in Europe, following FDA approval in the US. The QUILT 3.032 trial showed a 71% complete response rate for ...

How to listen, contact us and sign up for the newsletter Why is China building the world’s biggest dam? Why is China building the world’s biggest hydropower dam?

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Dr. Kamat traces the development of treatment options from the establishment of BCG-unresponsive disease criteria to the current array of approved and emerging therapies, including pembrolizumab, ...